SCHEMBL48810

SCHEMBL48810

COCCNS(=O)(=O)c1ccc(-c2sc(NC(C)=O)nc2C)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 15/20 0.66
PIK3CG P48736 14/20 0.66
PIK3CA P42336 11/20 0.66
PIK3CB P42338 10/20 0.66
PIK3C3 Q8NEB9 2/20 0.57
PIK3C2A O00443 1/20 0.57
PIK3C2B O00750 1/20 0.57
PI4KA P42356 1/20 0.57
PRKDC P78527 1/20 0.57
PI4KB Q9UBF8 1/20 0.57
ALDH1A1 P00352 2/20 0.55
LMNA P02545 2/20 0.55
HPGD P15428 2/20 0.55
KDM4E B2RXH2 1/20 0.55
NPC1 O15118 1/20 0.55
MAPT P10636 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HTT P42858 1/20 0.54
PIK3R1 P27986 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48485 0.88 PIK3CD (0.72) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48588 0.85 PIK3CG (0.73) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48422 0.85 PIK3CD (0.84) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48444 0.84 PIK3CD (0.65) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48492 0.83 PIK3CG (0.77) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48586 0.82 PIK3CD (0.58) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL12342399 0.81 PIK3CD (0.78) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48857 0.80 PIK3CG (1.00) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL48516 0.80 PIK3CG (0.81) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3
SCHEMBL1545939 0.80 PIK3CD (0.81) PIK3CDPIK3CGPIK3CAPIK3CBPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP claimed
EP-2311818-B1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug NOVARTIS AG (CH) 2013-01-16 EP disclosed
US-8129541-B2 5-phenylthiazole derivatives and use as PI3 kinase inhibitors NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-1480962-B1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS NOVARTIS AG (CH) 2011-08-24 EP disclosed
EP-2311818-A1 Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug Novartis AG (CH) 2011-04-20 EP disclosed
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS BRUCE IAN 2010-04-15 US disclosed
US-7687637-B2 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors NOVARTIS AG (CH) 2010-03-30 US disclosed
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors NOVARTIS AG (CH) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093690-A1 5-PHENYLTHIAZOLE DERIVATIVES AND USE AS PI3 KINASE INHIBITORS PIK3CA, PIK3R5, PIP5K1B PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885
US-20050119320-A1 5-phenylthiazole derivatives and use as pi3 kinase inhibitors PIK3CA, PIK3R5, PIP5K1B PIK3CD 4/4885PIK3CG 8/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.